Ciprocopan China approval gives PNH patients a new once-daily oral Factor B treatment option
Nuvectis Pharma’s ciprocopan wins China approval for PNH. Read how the once-daily Factor B drug could reshape the global treatment race.
Pharma & Biotech
Pharma & Biotech
Novartis expands oncology pipeline with $1.5bn Myricx Bio acquisition
Novartis is acquiring Myricx Bio for up to $1.5 billion to gain control of a new NMT inhibitor payload platform, but the lead antibody-drug conjugates have not yet entered human trials.
Pharma & Biotech
Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?
Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.
Pharma & Biotech
Degron Therapeutics extends Series A as DEG6498 enters the harder phase of cancer drug validation
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.
Pharma & Biotech
Novartis acquires SNV4818 from Synnovation in $3bn deal to reclaim ground in mutant PI3Ka breast cancer space
Novartis acquires SNV4818, a next-gen mutant-selective PI3Ka inhibitor, for up to $3bn. What this means for the HR+/HER2- breast cancer market. Read now.
Pharma & Biotech
Argo Biopharma’s RNAi therapy targets Lp(a): What Phase 2b with Novartis could prove
Novartis advances Argo Biopharma’s BW-20829 into Phase 2b to target lipoprotein(a). Explore what this means for RNAi adoption in cardiovascular therapeutics.
Pharma & Biotech
Could Novartis change the ITP playbook with just four doses of ianalumab?
Can four doses replace chronic ITP therapy? Find out how Novartis’ ianalumab performed in the VAYHIT2 trial and what it could mean for autoimmune care.